Abivax

📍 Paris, France🗓 Founded 2013👥 49 employees💰 Last funded Jan 2014
Biotechnology🌐 abivax.com
Website LinkedIn
Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body’s natural immune system mechanisms to treat diseases. With several programs in clinical trials as well as in research and preclinical development, Abivax’s pipeline is strong and diversified addressing many unmet medical needs. Abivax is currently targeting different inflammatory diseases within its clinical trial program with lead compound obefazimod: 1) Treatment Inflammatory Bowel Disease (IBD), specifically ulcerative colitis and Crohn's disease 2) Treatment of rheumatoid arthritis The second drug candidate, ABX196, is being tested in a clinical study for the treatment of liver cancer (HCC).
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2013
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Abivax?
Abivax has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Abivax last raise funding?
The most recent investment in Abivax recorded on gritt.io was in January 2014.
When was Abivax founded?
Abivax was founded in 2013.
What industry is Abivax in?
Abivax operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Abivax based?
Abivax is headquartered in Paris, France.